MOTS-c
16-amino-acid mitochondrial-derived peptide
Naturally occurring 16-amino-acid mitochondrial-derived peptide studied in metabolic stress, exercise and ageing biology, with no established human therapeutic exposure data.
Reference dose
5–10 mg
Source-specific educational reference, not an individualized recommendation.
Reference schedule
2–3× weekly · 8–12 weeks
New to peptide research?
This page gets detailed quickly.
Profiles include evidence, formats, units, source-specific reference amounts and, where relevant, device details. If any of those terms are unfamiliar, do not guess your way through them. Start with a Personalised Guide and we will put the foundations in the right order for you.
At a glance
Length
16 amino acids
A mitochondrial-derived peptide encoded within 12S rRNA.
Human evidence
Endogenous measurements
Human studies mainly measure naturally occurring MOTS-c rather than administering it.
Treatment evidence
Mostly animal / cell
Experimental administration data are largely preclinical.
Regulatory status
Not FDA approved
FDA reviewed MOTS-c-related substances for compounding in 2026.
What it is
MOTS-c is a naturally occurring mitochondrial-derived peptide encoded by a short open reading frame within mitochondrial 12S rRNA.
It has attracted interest because mitochondria are not only energy-producing organelles but also signalling systems that can communicate metabolic stress to the rest of the cell and body.
Research focus
How it works
MOTS-c is encoded within mitochondrial 12S rRNA and has been studied as a mitochondrial-to-nuclear stress signal. Experimental work links it to AMPK-related metabolic pathways, adaptive gene expression and skeletal-muscle energy homeostasis.
Important context
Humans naturally produce MOTS-c, and human studies have measured endogenous MOTS-c around exercise. That is not the same as evidence that injected synthetic MOTS-c is safe or effective as a drug. FDA states that it has not identified human exposure data for drug products containing MOTS-c.
What it is studied for
Metabolic research examines glucose handling, insulin sensitivity, fat metabolism and responses to metabolic stress.
Exercise research examines whether endogenous MOTS-c participates in adaptation to physical activity and skeletal-muscle stress.
Ageing research explores whether mitochondrial signalling contributes to age-related changes in physical capacity and metabolic resilience.
More contextEndogenous human biology is not a treatment trialSee the deeper context, evidence details and practical distinctions behind this profile.
The strongest human observations involve naturally occurring MOTS-c levels in blood or muscle before and after exercise. Experimental treatment studies showing improved metabolism or physical capacity are primarily in cells and animals.
This distinction matters because commercial injectable protocols often present mouse treatment findings or endogenous-human measurements as if they were clinical dosing evidence.
- MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA.
- Human exercise studies have reported changes in endogenous skeletal-muscle or circulating MOTS-c, but they did not administer MOTS-c as a therapeutic drug.
- FDA's 2026 compounding review states that it did not identify human exposure data for drug products containing MOTS-c.
- In July 2026 FDA proposed that MOTS-c free base and MOTS-c acetate not be included on the 503A Bulks List.
Why people are interested
What makes MOTS-c worth researching.
Human endogenous biomarker studies
Exercise-responsive biology
Human studies have reported exercise-associated changes in endogenous MOTS-c in skeletal muscle or circulation, supporting a role in exercise-related mitochondrial signalling.
Preclinical
Metabolic stress signalling
Cell and animal studies link MOTS-c to AMPK-related metabolic regulation, stress adaptation and insulin-sensitivity pathways.
Animal research
Physical capacity in animals
Experimental MOTS-c administration improved physical performance and age-related functional measures in mouse studies.
No established human drug-exposure data
Human therapeutic gap
FDA states it has not identified human exposure data for drug products containing MOTS-c, leaving injected human efficacy and safety unestablished.
Evidence
Where the evidence is strongest, and what kind of evidence it is.
Human · small mechanistic studies
Endogenous exercise response
Studies in healthy volunteers measured MOTS-c in muscle or plasma around exercise and reported exercise-associated changes. Participants were not treated with exogenous MOTS-c.
Animal + mechanistic
Ageing and performance
Mouse experiments reported improved physical capacity across age groups after MOTS-c treatment and identified stress-adaptation and muscle-metabolism pathways.
Mostly preclinical
Metabolic research
Animal and cellular studies have explored insulin sensitivity, glucose metabolism, obesity-related physiology and mitochondrial stress responses.
Regulatory evaluation · 2026
FDA compounding review
FDA reported no identified human exposure data for MOTS-c drug products and proposed that MOTS-c free base and acetate not be included on the 503A Bulks List.
Human research
Small human exercise studies have measured endogenous MOTS-c in skeletal muscle or circulation and reported exercise-associated changes.
These studies demonstrate that MOTS-c is part of human biology, but they do not establish the safety, pharmacokinetics or efficacy of injected synthetic MOTS-c.
FDA's 2026 review states that it did not identify human exposure data for drug products containing MOTS-c.
Preclinical research
Mouse and cell studies report effects on metabolic homeostasis, insulin sensitivity, skeletal-muscle function and adaptation to metabolic stress.
A 2021 Nature Communications study reported that experimental MOTS-c treatment improved physical performance in young, middle-aged and old mice and altered muscle stress-response pathways.
Mechanistic reviews describe AMPK, folate-AICAR metabolism and mitochondrial-to-nuclear gene regulation as recurring research themes.
Reference dosing
Reference amount, schedule and conversion.
A reference amount is only useful when you know the formulation, concentration and delivery device it belongs to. Do not transfer a vial amount into a pen, a pen click count into another pen, or a syringe-unit number into a different concentration.
01
Identify the format
Vial, reusable cartridge pen, prefilled multi-dose pen or single-dose autoinjector.
02
Confirm concentration
Know the total peptide amount and liquid volume or the manufacturer/vendor concentration.
03
Understand the units
Keep mg/mcg, mL and syringe units or device clicks separate.
04
Then use the reference
Only convert a known reference amount with the calculator that matches the actual device.
Source-specific reference
5–10 mg
2–3× weekly · 8–12 weeks
The 5–10 mg range is a Pep Report research reference. It is educational context rather than a clinically validated individualized dose.
Calculator connection
Choose the calculator that matches the actual formulation. The calculator converts numbers you already know; it does not choose the target amount.
The vial calculator can convert known peptide amount and liquid volume into concentration. It cannot validate the identity of a MOTS-c product or turn a research reference range into a supported human treatment dose.
Storage
Start with the format. Then verify the exact product.
Rule of thumb, not a product instruction
Storage belongs to the exact formulation. Generic advice can orient you, but the label, pharmacy directions or formulation-specific stability data should determine the final temperature and usable-life limits.
Pens
Treat a pen as a finished drug-device product: protect it from unnecessary heat and light, do not freeze unless the exact label explicitly permits it, and use that device's own unopened and in-use storage window.
Vials
Treat dry and reconstituted vials as different stability states. Refrigeration after mixing is common for some formulations but is not a universal peptide rule.
Product-specific notes
There is no FDA-approved MOTS-c product label establishing standardized storage or stability instructions for therapeutic use.
Research-vial handling depends on the actual formulation and supplier documentation.
Practical reference
Formats
Vial / injectable research formats
Reconstitution & units
Adding liquid changes concentration, not the total amount of peptide in the vial.
There is no clinically validated human MOTS-c reconstitution or dosing protocol.
mg describes peptide amount; mL and U-100 units describe liquid volume.
The vial calculator performs concentration arithmetic only and should not be interpreted as validating the research dose reference.
Safety, status & open questionsOpen the practical cautionsMOTS-c is an investigational research peptide, not an approved obesity, longevity or exercise-performance medicine. Human endogenous-biology studies should not be presented as clinical evidence for injected MOTS-c.
Open questions
Human therapeutic pharmacokinetics, dose-response relationships and long-term safety are not established.
Endogenous MOTS-c levels measured in human exercise studies cannot be converted into a therapeutic injection dose.
Animal performance and metabolic effects may not translate to clinically meaningful outcomes in humans.
Commercial products may vary in chemical form, identity, purity and concentration.
Regulatory notes
MOTS-c is not an FDA-approved drug.
FDA's 2026 review states that it did not identify human exposure data for drug products containing MOTS-c.
In July 2026 FDA proposed that MOTS-c free base and MOTS-c acetate not be included on the 503A Bulks List.
Practical notes
Human safety data for administered MOTS-c are insufficient to define a reliable adverse-effect profile.
FDA has raised potential immunogenicity and peptide-characterization concerns for compounded MOTS-c-related substances.
Injectable research products add independent risks involving sterility, identity, purity and concentration.
Unknown long-term metabolic or endocrine effects remain an important uncertainty when moving from endogenous biology to pharmacologic exposure.
Common mistakes
Treating an exercise study measuring natural MOTS-c as though researchers injected MOTS-c into participants.
Converting mouse doses or effects into a human longevity or performance protocol.
Presenting the 5–10 mg research range as a clinically validated human dose.
Assuming a vial sold as MOTS-c is chemically equivalent to the peptide form studied in a particular paper.
Common questions
Has MOTS-c been given to humans in clinical trials?
FDA's 2026 compounding review states that it did not identify human exposure data for drug products containing MOTS-c. Human studies commonly cited online mainly measure naturally occurring MOTS-c.
Why do human exercise studies matter?
They show that MOTS-c is part of human mitochondrial and exercise biology, but they do not establish injected MOTS-c as an effective or safe treatment.
Is MOTS-c an approved longevity or weight-loss drug?
No. It is not FDA approved for those or any other therapeutic indication.
What does the vial calculator do here?
It only converts known vial strength and liquid volume into concentration. It does not choose or validate a human MOTS-c dose.
Related peptides & blends
SS-31 / Elamipretide
Mitochondrial cardiolipin-binding tetrapeptide now FDA-approved as Forzinity for improving muscle strength in Barth syndrome patients weighing at least 30 kg.
Open reference →NAD+
Essential cellular redox cofactor and signaling substrate widely marketed for energy and longevity, while direct IV NAD+ wellness outcomes remain insufficiently established.
Open reference →References
MOTS-c and exercise / age-dependent physical decline
Nature Communications / PubMed · 2021
Acute exercise and circulating mitochondrial-derived peptides in humans
PubMed · 2021
MOTS-c mechanisms related to stress, metabolism and ageing — review
Journal of Translational Medicine / PubMed · 2023
FDA July 2026 PCAC meeting — MOTS-c-related bulk substances
U.S. FDA · 2026
FDA briefing — MOTS-c-related bulk drug substances
U.S. FDA · 2026